Table 5 Multivariate analysis of factors associated with DFS and OS in post- menopausal patients

Neo-adjuvant therapy (Yes vs. No)

2.24 (1.51–3.30)

<  0.001

2.18 (1.30–3.66)

0.003

Breast surgery (BCS vs. Mastectomy)

/

/

0.92 (0.59–1.44)

0.722

Tumor size (>  2.0 cm vs. ≤ 2.0 cm)

1.46 (1.13–1.89)

<  0.001

1.53 (1.06–2.20)

0.024

ALN status (Positive vs. Negative)

1.74 (1.34–2.26)

<  0.001

2.23 (1.55–3.19)

<  0.001

Histological grade

<  0.001

0.004

III vs. I/II

1.54 (1.13–2.09)

1.53 (1.00–2.36)

NA vs. I/II

2.05 (1.48–2.85)

2.08 (1.31–3.29)

ER

0.043

< 0.001

10–49% vs. 1–9%

1.56 (0.76–3.21)

1.01 (0.47–2.18)

≥ 50% vs. 1–9%

1.02 (0.51–2.02)

0.45 (0.22–0.93)

PR (≥ 20% vs. <  20%)

0.84 (0.64–1.09)

0.194

0.76 (0.52–1.13)

0.177

Ki-67 (≥ 14% vs. <  14%)

1.50 (1.14–1.99)

0.004

1.39 (0.94–2.07)

0.098

Radiotherapy (Yes vs. No)

0.91 (0.66–1.25)

0.549

1.13 (0.71–1.79)

0.605

Chemotherapy (Yes vs. No)

1.12 (0.83–1.52)

0.466

/

/

Endocrine therapy (Yes vs. No)

0.56 (0.37–0.86)

0.007

0.53 (0.31–0.91)

0.021

Group (HER2-pos-T vs. HER2-neg)

0.52 (0.32–0.85)

0.005

0.37 (0.17–0.77)

0.008